Bio-techne Corp. (TECH)

$74.81

-1.06

(-1.4%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Bio-techne Corp.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 272.59M → 303.42M (in $), with an average increase of 10.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 27.46M → 49.05M (in $), with an average increase of 44.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.1% return, outperforming this stock by 78.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 271.9%

Performance

  • $74.63
    $75.94
    $74.81
    downward going graph

    0.24%

    Downside

    Day's Volatility :1.73%

    Upside

    1.49%

    downward going graph
  • $51.42
    $89.19
    $74.81
    downward going graph

    31.27%

    Downside

    52 Weeks Volatility :42.35%

    Upside

    16.12%

    downward going graph

Returns

PeriodBio-techne Corp.Sector (Health Care)S&P500
3 Months
4.08%
0.6%
6.3%
6 Months
-1.59%
8.9%
15.5%
1 Year
-3.38%
10.2%
24.1%
3 Years
-30.72%
17.8%
31.4%

Highlights

Market Capitalization
12.1B
Book Value
$12.79
Dividend Share
0.32
Dividend Yield
0.42%
Earnings Per Share (EPS)
1.25
PE Ratio
61.5
PEG Ratio
1.15
Wall Street Target Price
83.77
Profit Margin
17.59%
Operating Margin TTM
23.74%
Return On Assets TTM
6.11%
Return On Equity TTM
10.4%
Revenue TTM
1.2B
Revenue Per Share TTM
7.32
Quarterly Revenue Growth YOY
3.2%
Gross Profit TTM
770.2M
EBITDA
326.3M
Diluted Eps TTM
1.25
Quarterly Earnings Growth YOY
-0.28
EPS Estimate Current Year
1.78
EPS Estimate Next Year
2.03
EPS Estimate Current Quarter
0.45
EPS Estimate Next Quarter
0.5

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Bio-techne Corp.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
17
17
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11.98%

Current $74.81
Target $83.77

Company Financials

FY18Y/Y Change
Revenue
643.0M
↑ 14.21%
Net Income
125.4M
↑ 62.19%
Net Profit Margin
19.49%
↑ 5.76%
FY19Y/Y Change
Revenue
714.0M
↑ 11.04%
Net Income
96.1M
↓ 23.36%
Net Profit Margin
13.46%
↓ 6.03%
FY20Y/Y Change
Revenue
738.7M
↑ 3.46%
Net Income
229.3M
↑ 138.67%
Net Profit Margin
31.04%
↑ 17.58%
FY21Y/Y Change
Revenue
931.0M
↑ 26.04%
Net Income
140.4M
↓ 38.76%
Net Profit Margin
15.08%
↓ 15.96%
FY22Y/Y Change
Revenue
1.1B
↑ 18.75%
Net Income
272.1M
↑ 93.75%
Net Profit Margin
24.61%
↑ 9.53%
FY23Y/Y Change
Revenue
1.1B
↑ 2.81%
Net Income
285.3M
↑ 4.86%
Net Profit Margin
25.1%
↑ 0.49%
Q4 FY22Q/Q Change
Revenue
271.6M
↑ 0.71%
Net Income
50.0M
↓ 44.16%
Net Profit Margin
18.41%
↓ 14.8%
Q1 FY23Q/Q Change
Revenue
294.1M
↑ 8.31%
Net Income
70.2M
↑ 40.42%
Net Profit Margin
23.87%
↑ 5.46%
Q2 FY23Q/Q Change
Revenue
301.3M
↑ 2.44%
Net Income
75.5M
↑ 7.5%
Net Profit Margin
25.05%
↑ 1.18%
Q3 FY23Q/Q Change
Revenue
276.9M
↓ 8.09%
Net Income
51.0M
↓ 32.45%
Net Profit Margin
18.41%
↓ 6.64%
Q4 FY23Q/Q Change
Revenue
272.6M
↓ 1.57%
Net Income
27.5M
↓ 46.14%
Net Profit Margin
10.08%
↓ 8.33%
Q1 FY24Q/Q Change
Revenue
303.4M
↑ 11.31%
Net Income
49.1M
↑ 78.62%
Net Profit Margin
16.17%
↑ 6.09%
FY18Y/Y Change
Total Assets
1.6B
↑ 2.35%
Total Liabilities
514.1M
↓ 15.15%
FY19Y/Y Change
Total Assets
1.9B
↑ 18.28%
Total Liabilities
718.8M
↑ 39.83%
FY20Y/Y Change
Total Assets
2.0B
↑ 7.6%
Total Liabilities
646.4M
↓ 10.08%
FY21Y/Y Change
Total Assets
2.3B
↑ 11.61%
Total Liabilities
691.7M
↑ 7.01%
FY22Y/Y Change
Total Assets
2.3B
↑ 1.41%
Total Liabilities
593.8M
↓ 14.16%
FY23Y/Y Change
Total Assets
2.6B
↑ 14.99%
Total Liabilities
672.2M
↑ 13.2%
Q4 FY22Q/Q Change
Total Assets
2.4B
↑ 0.54%
Total Liabilities
536.3M
↓ 10.55%
Q1 FY23Q/Q Change
Total Assets
2.6B
↑ 10.0%
Total Liabilities
710.0M
↑ 32.39%
Q2 FY23Q/Q Change
Total Assets
2.6B
↑ 1.5%
Total Liabilities
672.2M
↓ 5.33%
Q3 FY23Q/Q Change
Total Assets
2.8B
↑ 4.42%
Total Liabilities
757.6M
↑ 12.71%
Q4 FY23Q/Q Change
Total Assets
2.7B
↓ 0.89%
Total Liabilities
767.2M
↑ 1.26%
Q1 FY24Q/Q Change
Total Assets
2.7B
↓ 0.35%
Total Liabilities
706.8M
↓ 7.87%
FY18Y/Y Change
Operating Cash Flow
170.4M
↑ 18.77%
Investing Cash Flow
-38.7M
↓ 87.35%
Financing Cash Flow
-99.2M
↓ 152.37%
FY19Y/Y Change
Operating Cash Flow
181.6M
↑ 6.6%
Investing Cash Flow
-336.8M
↑ 770.01%
Financing Cash Flow
134.4M
↓ 235.48%
FY20Y/Y Change
Operating Cash Flow
205.2M
↑ 12.99%
Investing Cash Flow
27.1M
↓ 108.04%
Financing Cash Flow
-183.8M
↓ 236.77%
FY21Y/Y Change
Operating Cash Flow
352.2M
↑ 71.61%
Investing Cash Flow
-243.5M
↓ 998.75%
Financing Cash Flow
-62.6M
↓ 65.97%
FY22Y/Y Change
Operating Cash Flow
325.3M
↓ 7.64%
Investing Cash Flow
-96.9M
↓ 60.23%
Financing Cash Flow
-242.9M
↑ 288.25%
FY23Y/Y Change
Operating Cash Flow
254.4M
↓ 21.79%
Investing Cash Flow
-265.6M
↑ 174.29%
Financing Cash Flow
22.6M
↓ 109.31%
Q4 FY22Q/Q Change
Operating Cash Flow
64.4M
↑ 14.81%
Investing Cash Flow
-109.0K
↓ 99.45%
Financing Cash Flow
-72.2M
↑ 126.99%
Q1 FY23Q/Q Change
Operating Cash Flow
50.5M
↓ 21.51%
Investing Cash Flow
-241.1M
↑ 221088.99%
Financing Cash Flow
150.8M
↓ 308.93%
Q2 FY23Q/Q Change
Operating Cash Flow
83.4M
↑ 65.02%
Investing Cash Flow
-4.8M
↓ 98.03%
Financing Cash Flow
-24.2M
↓ 116.06%

Technicals Summary

Sell

Neutral

Buy

Bio-techne Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bio-techne Corp.
Bio-techne Corp.
-9.32%
-1.59%
-3.38%
-30.72%
44.22%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bio-techne Corp.
Bio-techne Corp.
61.5
61.5
1.15
1.78
0.1
0.06
0.0
12.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bio-techne Corp.
Bio-techne Corp.
Buy
$12.1B
44.22%
61.5
17.59%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Institutional Holdings

  • Vanguard Group Inc

    11.60%
  • BlackRock Inc

    11.26%
  • State Street Corporation

    4.04%
  • T. Rowe Price Associates, Inc.

    3.65%
  • BAMCO Inc

    3.17%
  • Morgan Stanley - Brokerage Accounts

    2.66%

Corporate Announcements

  • Bio-techne Corp. Dividends March,2024

    In the quarter ending March,2024. Bio-techne Corp. has declared dividend of $0.08

    Read More

Company Information

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Organization
Bio-techne Corp.
Employees
3200
CEO
Mr. Kim Kelderman
Industry
Health Technology

FAQs